Paid Advertorial
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
“Our Omni-Omic technology was developed to help empower AI platforms and thereby transform
non-invasive healthcare solutions to detect cancers and other diseases as early as possible.
GEDiCube’s innovative deep learning algorithms have created robust multi-omics panels that perform
remarkably well. Together, I believe we will change the field.”
“There is enormous power in applying AI to multiple omics data layers that can be detected from a
vial of blood from every patient with cancer. I believe that integrating Cyclomics into GEDiCube
will allow us to gain greater accuracy and widespread Omni-omic measurements through next-generation
sequencing and enter the cancer monitoring market this year. I consider that to be a significant
step towards bringing early detection of cancer to its inflection point.”
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence, thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.
At GEDiCube, we are committed to the early detection of cancer, to intervene at a stage where treatment can be most effective. We have developed an award-winning AI Technology that significantly accelerates early cancer detection and diagnosis at an early stage and its recurrence via liquid biopsy. Our platform, “ The Cube,” brings together proprietary artificial intelligence (AI/ML) technology and algorithms, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to accelerate precision medicine and enable breakthrough changes in cancer care. As of this morning GEDiCube will operate under its new name, RenovaroCube.
With a NASDAQ listing (NASDAQ: RENB), RENB offers investors a compelling opportunity to participate in the future of healthcare. Its innovative pipeline, strategic collaborations, and potential for significant market growth make RENB an attractive investment proposition. By transforming healthcare and offering hope for a future free from toxic chemotherapy, RENB is poised to make a profound impact on the lives of millions worldwide.
If there is a way to prevent this devastating disease from happening, it could completely change the healthcare landscape going forward. This is where Renovaro Biosciences Inc (NASDAQ: RENB) is leading in innovation.
Renovaro Biosciences Inc. (NASDAQ: RENB) is a pioneering biotechnology company at the forefront of revolutionizing healthcare. Focused on developing advanced allogenic cell and gene therapies, Renovaro is committed to addressing significant unmet needs in cancer, HIV, and HBV treatment. With a strategic emphasis on innovative technologies and cutting-edge research, the company is reshaping the landscape of modern medicine.
Renovaro's mission is anchored in its dedication to transforming cancer care. By leveraging groundbreaking gene-modified cell therapies, the company aims to offer hope to patients battling solid tumors, a critical area where traditional treatments often fall short. Additionally, Renovaro's pioneering approach to HIV treatment presents a potential breakthrough in combating the virus and improving patient outcomes worldwide.
Committed to advancing healthcare, Renovaro collaborates with renowned institutions such as UCLA and the Fred Hutchinson Cancer Research Center. Through these strategic partnerships, the company accelerates the development of its therapies and maximizes their potential to impact patients' lives positively.
As a NASDAQ-listed company (NASDAQ: RENB), Renovaro offers investors a compelling opportunity to participate in the dynamic field of biotechnology. With a focus on innovation, collaboration, and market growth, Renovaro is poised to lead the way in transforming healthcare and shaping a brighter future for patients worldwide.
Leveraging allogenic cells offers numerous advantages to our development strategy:
Renovaro BioSciences collaborates with Dr. Anahid Jewett from UCLA to further investigate the efficacy of our approach in pancreatic cancer. Dr. Jewett's innovative mouse model mimics the human immune system, offering invaluable insights for advancing cancer treatment.
RENB-DC11 treated animals compared to controls
Delayed injection of RENB-DC11 in mice with established luciferase labeled pancreas tumor, stopped progression and showed drastic tumor size regression in 2/3 mice (one mouse had no tumor detection 4wk post dosing), whereas all untreated mice showed massive tumor progression.
"Despite advances in treatment, HIV remains a global challenge. Antiretroviral therapy has transformed HIV from a death sentence to a manageable condition, yet it comes with challenges such as lifelong therapy, high costs, and risks of side effects. With drug resistance on the rise, there's a critical need for innovative solutions. Stigma and discrimination further complicate the situation.
Over 40% of those needing therapy lack access, and HIV claims over a million lives annually with millions more newly infected. A cure or preventive vaccine holds the promise of transforming countless lives worldwide."
Renovaro BioSciences aims to boost the immune system against HIV through vaccination, offering protection for uninfected individuals and potentially controlling the virus in those already infected. Their innovative approach utilizes immune response induction from donor cells. Promising in vitro results have led to non-human primate studies at the Fred Hutchinson Cancer Research Center, with preliminary findings expected by late 2023. Human studies could follow in late 2024
"Renovaro BioSciences presents a groundbreaking solution for HIV treatment by targeting CCR5 expression, crucial for HIV entry into cells. Their ALDH gene modification technology aims to enhance engraftment of gene-modified stem cells without the need for immune system ablation, potentially eliminating the need for Antiretroviral Treatment (ART). While initial studies showed promising results, further development of RENB-HV01 was deemed costly. As a strategic move, Renovaro sub-licensed the ALDH gene modification to Caring Cross, who aims to integrate it into their CAR-T cell therapy for enhanced engraftment."
"Renovaro BioSciences is exploring RENB-HV21, a promising HIV treatment utilizing allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). These cells, believed to play a key role in controlling the virus, offer innovative potential for HIV therapy. Renovaro holds an exclusive license for the underlying patent, with successful pre-IND studies completed. However, due to priority shifts to the Oncology pipeline, immediate clinical trials for RENB-HV21 are not planned."
RENB-HB-01 is currently in the early pre-clinical phase, with ongoing exploration of different gene therapy design approaches. Pending successful results from these explorations, we anticipate initiating the regulatory process by the first half of 2024. However, our primary focus and investment priority lie in advancing the oncology platform, starting with pancreatic cancer research and development.
Our integrated platforms encompass innovative interventions in advanced cell and gene therapies that provide hope for cures and/or life-long remissions for devastating diseases. Because of the relative ease of administration, our potentially ground-breaking interventions could be used throughout the world to transform the lives of millions of people.
Renovaro Biosciences pioneers cutting-edge cancer therapies targeting immune evasion. Our innovative approach, leveraging genetically engineered dendritic cells, bypasses tumor defenses, and enhances tumor eradication. RENB-DC11, a breakthrough therapy, harnesses genetic modifications to bolster immune signaling, effectively targeting aggressive solid tumors.
“The fusion of AI and biotech opens up new horizons in healthcare. We have been advancing strategic partnerships with leading academic centers and technology companies while working to expand our existing relationship with NVIDIA. We believe our combined capabilities will help to accelerate both the ability to detect and treat cancer and other diseases.”
By Dr. van Kalken added,In the realm of modern medicine, the quest to conquer cancer and infectious diseases stands as one of humanity's greatest challenges. Renovaro Biosciences Inc. (NASDAQ: RENB) emerges as a beacon of hope, dedicated to pioneering advanced allogenic cell and gene therapies to combat these formidable foes.
With a comprehensive pipeline spanning oncology, HIV, and HBV, Renovaro is at the forefront of cutting-edge medical innovation. In the oncology sphere, the company's groundbreaking platform targets solid tumors, leveraging genetically modified dendritic cells to bypass immune evasion and enhance tumor eradication. Promising preclinical results from RENB-DC11 demonstrate its efficacy against aggressive forms of solid tumors.
In the battle against HIV, Renovaro's innovative approach seeks to boost immune responses through preventive and therapeutic vaccines, potentially transforming the lives of millions worldwide. Meanwhile, their exploration of allogenic Natural Killer and Gamma Delta T-Cells presents a novel avenue for HIV treatment.
Additionally, Renovaro's foray into HBV gene therapy signals a promising step towards eradicating virus-infected cells, offering hope for those afflicted by this persistent infection.
With a focus on leveraging banked allogenic cell therapy and strategic collaborations with esteemed institutions like UCLA, Renovaro is poised to revolutionize healthcare delivery. As the company advances its mission to develop definitive cures and therapies, now is the time to keep Renovaro Biosciences Inc. on your radar as a leading force in the fight against cancer and infectious diseases.